TCT 2021 | Allogeneic, off-the-shelf, COVID-19-specific T-cells
Spyridoula Vasileiou
• 8 Feb 2021
Spyridoula Vasileiou, PhD, Baylor College of Medicine, Texas Children’s Hospital, Houston, TX, discusses the development of allogeneic, off-the-shelf SARS-Cov2 specific T-cells to treat high-risk patients with COVID-19. Dr Vasileiou highlights the feasibility of generating COVID-19-specific T-cells from convalescent individuals and comments on an ongoing clinical trial evaluating this product in hospitalized patients with COVID-19. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
